South East Asia Diabetic Retinopathy Market Size & Outlook, 2025-2033
South East Asia Diabetic Retinopathy Market Insights
- As per Reed Intelligence insights, the South East Asia Diabetic Retinopathy Market stood at USD 358.15 Million in 2024 and is anticipated to grow to USD 652.43 Million by 2033.
- The South East Asia market is expected to advance at a CAGR of 6.85% from 2026 through 2033.
- In 2024, Proliferative Diabetic Retinopathy accounted for the highest share of the By Type market size.
- During the forecast period, Proliferative Diabetic Retinopathy is set to register the highest growth, making it the most lucrative By Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, South East Asia held 3.92% of the global Diabetic Retinopathy Market size.
- By 2033, United States is anticipated to capture the largest share of the global Diabetic Retinopathy Market.
- In Asia Pacific, China is expected to lead the regional Diabetic Retinopathy Market size by 2033.
- Singapore will remain the fastest-growing market in Asia Pacific, reaching USD 94.06 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 358.15 Million |
| Market Size In 2033 | USD 652.43 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 6.85% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South East Asia Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 230.58 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South East Asia Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 165.11 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
